Conditions: Non Small Cell Lung Cancer
Keywords: lung cancer non small cell lung cancer
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 8
Healthy volunteers: no

Brief summary:
To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.

Detailed description:

Arms:
arm 1: Participants self-administered entinostat in combination with continued erlotinib self-administration.

"Erlotinib-responsive" participants are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months. arm 2: Participants self-administered entinostat in combination with continued erlotinib self-administration.

"Erlotinib-nonresponsive" participants are those who either progressed immediately during treatment with erlotinib (after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months.

Interventions: intervention 1: Entinostat intervention 2: Erlotinib
Intervention descriptions: intervention 1: Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles intervention 2: Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles

Protocol document: